Form 4: Charles Theuer Acquires 22,500 Stock Options in 4D Molecular Therapeutics

Director Charles Theuer acquired 22,500 stock options in 4D Molecular Therapeutics on May 21, 2024, as part of the company's non-employee director compensation program.

Summary

• Charles Theuer, a director of 4D Molecular Therapeutics, acquired 22,500 stock options on May 21, 2024.
• The options were granted automatically under the company's non-employee director compensation program.
• The exercise price of the stock options is $25.15.
• The options vest in three tranches: 1/3 on May 21, 2025, and then in equal monthly installments until fully vested on May 21, 2027, contingent upon continued service.
• The stock options will vest in full upon the consummation of a Change in Control as defined in the 2020 Incentive Award Plan.
• The options expire on May 20, 2034.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting standard compensation practices. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects standard compensation practices for directors.

Key Dates